Centessa Pharmaceuticals plc (CNTA)
USD 16.51
(-6.19%)
USD 16.51
(-6.19%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -160.96 Million | -200.54 Million | -136.14 Million | -10.63 Million | -5.82 Million |
| Net Income | -151.67 Million | -216.2 Million | -381.85 Million | -10.66 Million | -5.06 Million |
| Depreciation & Amortization | 813.13 Thousand | 131 Thousand | 33.99 Thousand | - | 6000.00 |
| Deferred income taxes | -26.63 Million | -2.85 Million | -6.8 Million | - | 770.00 |
| Stock-based compensation | 29.39 Million | 24.96 Million | 14.85 Million | 336 Thousand | 236 Thousand |
| Change in working capital | -18.9 Million | -2.83 Million | -5.37 Million | -489 Thousand | -1 Million |
| Other non-cash items | 6.03 Million | -3.74 Million | 257.84 Million | 186 Thousand | -770.00 |
| Investing Cash Flow | -127.49 Million | -931 Thousand | 63.24 Million | - | - |
| Investments in PPE | -169.65 Thousand | -1.13 Million | -185.97 Thousand | - | - |
| Acquisitions | - | - | 63.43 Million | - | - |
| Investment purchases | -265.93 Million | - | - | - | - |
| Sales/Maturities of investments | 138.61 Million | - | - | - | - |
| Other Investing Activities | 1.00 | 206 Thousand | -1.00 | - | - |
| Financing Cash Flow | 21.19 Million | 457 Thousand | 660.06 Million | 1.36 Million | 9 Million |
| Debt repayment | - | - | -73.63 Million | -5.03 Million | -3.83 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | -11.99 Thousand | - | - |
| Common Stock Issuance | 21.19 Million | 717.55 Thousand | 586.44 Million | 10.07 Thousand | - |
| Other Financing Activities | 21.11 Million | -260.55 Thousand | 586.21 Million | 6.39 Million | 9 Million |
| Accounts receivables | -12.13 Million | -11.7 Million | -6.72 Million | - | - |
| Accounts payables | -2.73 Million | 6.35 Million | 4.15 Million | -49 Thousand | 855 Thousand |
| Inventory | -1.00 | 11.7 Million | -4.15 Million | - | - |
| Other working capital | -4.03 Million | -9.18 Million | 1.34 Million | -440 Thousand | -1.86 Million |
| Cash at beginning of period | 393.64 Million | 595.08 Million | 5 Million | 16.57 Million | 12.87 Million |
| Cash at end of period | 128.03 Million | 393.64 Million | 595.08 Million | 7.22 Million | 16.57 Million |
| Capital Expenditure | -169.65 Thousand | -1.13 Million | -185.97 Thousand | - | - |
| Effect of forex changes on cash | 615 Thousand | -418 Thousand | 1.9 Million | -75 Thousand | 520 Thousand |
| Net cash flow / Change in cash | -265.61 Million | -201.43 Million | 590.07 Million | -9.34 Million | 3.7 Million |
| Free Cash Flow | -161.13 Million | -201.68 Million | -136.32 Million | -10.63 Million | -5.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -43.81 Million | -38.04 Million | -37.15 Million | -151.67 Million | -38.64 Million | -24.88 Million |
| Depreciation & Amortization | 236 Thousand | 240 Thousand | 248.13 Thousand | 813.13 Thousand | 238 Thousand | 237 Thousand |
| Deferred income taxes | 567 Thousand | 434 Thousand | -135.32 Thousand | -26.63 Million | -2.89 Million | -23.63 Million |
| Stock-based compensation | 8.61 Million | 8.15 Million | 7.43 Million | 29.39 Million | 7.55 Million | 7.21 Million |
| Change in working capital | -5.87 Million | -9.16 Million | -3.44 Million | -18.9 Million | -4.44 Million | -5.66 Million |
| Other non-cash items | -300 Thousand | 1.1 Million | 1.95 Million | 6.03 Million | 795 Thousand | 2.67 Million |
| Investing Cash Flow | -55.45 Million | 16.76 Million | -18.28 Million | -127.49 Million | 48.7 Million | -71.09 Million |
| Investments in PPE | 1.55 | -0.47 | -28.03 Thousand | -169.65 Thousand | -43 Thousand | -10 Thousand |
| Acquisitions | - | - | 18.24 Million | - | -86.62 Million | - |
| Investment purchases | -120.53 Million | -19.99 Million | -70.24 Million | -265.93 Million | -37.49 Million | -71.08 Million |
| Sales/Maturities of investments | 65.07 Million | 36.76 Million | 51.98 Million | 138.61 Million | 86.62 Million | - |
| Other Investing Activities | -55.45 Million | 16.76 Million | -18.24 Million | 1.00 | 86.24 Million | -71.08 Million |
| Financing Cash Flow | 105.31 Million | 10.49 Million | 6.37 Million | 21.19 Million | 14.74 Million | 12 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 107.27 Million | 9.65 Million | 6.37 Million | 21.19 Million | 14.8 Million | 12.07 Thousand |
| Other Financing Activities | -1.95 Million | 838 Thousand | 6.36 Million | 21.11 Million | -65.08 Thousand | -75.00 |
| Accounts receivables | -5.55 Million | 1.2 Million | -7.96 Million | -12.13 Million | -2.32 Million | -6.19 Million |
| Accounts payables | -2.18 Million | -4.25 Million | 590.05 Thousand | -2.73 Million | 83 Thousand | -1.57 Million |
| Inventory | - | - | 1.00 | -1.00 | 2.32 Million | 6.19 Million |
| Other working capital | 1.86 Million | -6.12 Million | 3.92 Million | -4.03 Million | -4.52 Million | -4.08 Million |
| Cash at beginning of period | 118.21 Million | 128.03 Million | 171.49 Million | 393.64 Million | 145.22 Million | 259.98 Million |
| Cash at end of period | 127.37 Million | 118.21 Million | 128.03 Million | 128.03 Million | 171.49 Million | 145.22 Million |
| Capital Expenditure | 1.55 | -0.47 | -28.03 Thousand | -169.65 Thousand | -43 Thousand | -10 Thousand |
| Effect of forex changes on cash | -120 Thousand | 219 Thousand | -504 Thousand | 615 Thousand | 220 Thousand | 381 Thousand |
| Net cash flow / Change in cash | 9.15 Million | -9.81 Million | -43.46 Million | -265.61 Million | 26.27 Million | -114.76 Million |
| Free Cash Flow | -40.57 Million | -37.28 Million | -31.12 Million | -161.13 Million | -37.43 Million | -44.07 Million |
TENB
MRDH
NHOLF
BTOG
0J8Z
BP-B